Hims & Hers Health (NYSE:HIMS – Free Report) had its price objective lifted by Bank of America from $17.25 to $22.00 in a research note released on Monday morning, Benzinga reports. The brokerage currently has a buy rating on the stock.
Several other equities research analysts also recently issued reports on HIMS. Leerink Partnrs reiterated a market perform rating on shares of Hims & Hers Health in a report on Monday, February 26th. Imperial Capital upgraded Hims & Hers Health from an in-line rating to an outperform rating and set a $16.00 target price on the stock in a research note on Wednesday, February 28th. Piper Sandler increased their target price on shares of Hims & Hers Health from $11.00 to $13.00 and gave the company a neutral rating in a research report on Tuesday, May 7th. Deutsche Bank Aktiengesellschaft upped their price objective on Hims & Hers Health from $14.00 to $16.00 and gave the company a hold rating in a research note on Tuesday, May 7th. Finally, Jefferies Financial Group reissued a hold rating and issued a $15.00 price objective (down previously from $17.00) on shares of Hims & Hers Health in a report on Tuesday, April 16th. Seven investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of Moderate Buy and an average target price of $16.14.
Get Our Latest Report on Hims & Hers Health
Hims & Hers Health Stock Performance
Shares of HIMS stock opened at $20.50 on Monday. Hims & Hers Health has a fifty-two week low of $5.65 and a fifty-two week high of $21.44. The stock has a 50 day simple moving average of $14.53 and a two-hundred day simple moving average of $11.68. The company has a market cap of $4.40 billion, a P/E ratio of -2,049.50 and a beta of 1.08.
Hims & Hers Health (NYSE:HIMS – Get Free Report) last posted its quarterly earnings results on Monday, May 6th. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.03. The firm had revenue of $278.20 million during the quarter, compared to the consensus estimate of $270.37 million. Hims & Hers Health had a negative net margin of 0.24% and a negative return on equity of 0.70%. The business’s revenue was up 45.8% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.05) earnings per share. On average, research analysts predict that Hims & Hers Health will post 0.18 earnings per share for the current year.
Insider Buying and Selling
In other Hims & Hers Health news, COO Melissa Baird sold 11,750 shares of Hims & Hers Health stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $12.08, for a total value of $141,940.00. Following the transaction, the chief operating officer now directly owns 538,932 shares of the company’s stock, valued at approximately $6,510,298.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, COO Melissa Baird sold 11,750 shares of the business’s stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $12.08, for a total transaction of $141,940.00. Following the transaction, the chief operating officer now owns 538,932 shares in the company, valued at approximately $6,510,298.56. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Soleil Boughton sold 129,667 shares of the company’s stock in a transaction that occurred on Thursday, May 30th. The shares were sold at an average price of $20.55, for a total value of $2,664,656.85. Following the transaction, the insider now directly owns 156,855 shares of the company’s stock, valued at approximately $3,223,370.25. The disclosure for this sale can be found here. Insiders have sold a total of 723,975 shares of company stock worth $11,129,571 in the last 90 days. 17.71% of the stock is owned by company insiders.
Institutional Investors Weigh In On Hims & Hers Health
Several hedge funds have recently made changes to their positions in HIMS. Cetera Advisors LLC purchased a new position in Hims & Hers Health during the 1st quarter valued at about $396,000. Farallon Capital Management LLC increased its stake in shares of Hims & Hers Health by 3,890.5% during the first quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock valued at $25,928,000 after purchasing an additional 1,634,000 shares in the last quarter. Virtu Financial LLC purchased a new position in shares of Hims & Hers Health during the first quarter valued at approximately $638,000. Strategic Wealth Partners Ltd. bought a new stake in shares of Hims & Hers Health in the 1st quarter worth approximately $839,000. Finally, Bayesian Capital Management LP purchased a new stake in shares of Hims & Hers Health in the 1st quarter worth approximately $1,770,000. 63.52% of the stock is currently owned by institutional investors.
About Hims & Hers Health
Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.
Featured Stories
Receive News & Ratings for Hims & Hers Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Hims & Hers Health and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net
